Clinical Efficacy of Ofloxacin in Lower Respiratory Tract Infections

A Multicentre Study

C. Grassi, G. Gialdroni Grassi, P. Mangiarotti

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400mg (245 patients), 600mg (211) or 800mg (211). The mean duration of treatment was 8.77 ± 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8%). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8%). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.

Original languageEnglish
Pages (from-to)80-82
Number of pages3
JournalDrugs
Volume34
Issue number1
DOIs
Publication statusPublished - 1987

Fingerprint

Ofloxacin
Pathogens
Respiratory Tract Infections
Multicenter Studies
Skin
Exanthema
Clinical Trials
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Clinical Efficacy of Ofloxacin in Lower Respiratory Tract Infections : A Multicentre Study. / Grassi, C.; Gialdroni Grassi, G.; Mangiarotti, P.

In: Drugs, Vol. 34, No. 1, 1987, p. 80-82.

Research output: Contribution to journalArticle

Grassi, C. ; Gialdroni Grassi, G. ; Mangiarotti, P. / Clinical Efficacy of Ofloxacin in Lower Respiratory Tract Infections : A Multicentre Study. In: Drugs. 1987 ; Vol. 34, No. 1. pp. 80-82.
@article{2658311797604988b8d06f57bdf246b5,
title = "Clinical Efficacy of Ofloxacin in Lower Respiratory Tract Infections: A Multicentre Study",
abstract = "A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400mg (245 patients), 600mg (211) or 800mg (211). The mean duration of treatment was 8.77 ± 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8{\%}). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8{\%}). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.",
author = "C. Grassi and {Gialdroni Grassi}, G. and P. Mangiarotti",
year = "1987",
doi = "10.2165/00003495-198700341-00017",
language = "English",
volume = "34",
pages = "80--82",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical Efficacy of Ofloxacin in Lower Respiratory Tract Infections

T2 - A Multicentre Study

AU - Grassi, C.

AU - Gialdroni Grassi, G.

AU - Mangiarotti, P.

PY - 1987

Y1 - 1987

N2 - A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400mg (245 patients), 600mg (211) or 800mg (211). The mean duration of treatment was 8.77 ± 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8%). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8%). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.

AB - A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400mg (245 patients), 600mg (211) or 800mg (211). The mean duration of treatment was 8.77 ± 2.62 days. Satisfactory overall clinical results (i.e. cured or improved) were obtained in 612 of 667 patients (91.8%). Eradication of pathogens was achieved for 279 of 354 isolated strains (78.8%). Side effects were observed in 31 patients and consisted of gastrointestinal disturbance (22), skin rash (1), neurological disturbance (3) and others (5). No significant alteration of haematological parameters was reported.

UR - http://www.scopus.com/inward/record.url?scp=0023518275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023518275&partnerID=8YFLogxK

U2 - 10.2165/00003495-198700341-00017

DO - 10.2165/00003495-198700341-00017

M3 - Article

VL - 34

SP - 80

EP - 82

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 1

ER -